A Randomized Study of the Relative Bioavailability, Pharmacodynamics, Safety of SAR236553 (REGN727) After Single Subcutaneous Administration at 3 Different Injection Sites in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 30 Mar 2014
At a glance
- Drugs Alirocumab (Primary)
- Indications Hypercholesterolaemia; Hyperlipoproteinaemia type II
- Focus Pharmacokinetics
- Sponsors Sanofi
- 30 Mar 2014 Results presented at the 63rd Annual Scientific Session of the American College of Cardiology.
- 18 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.